LEGN
Legend Biotech Corp
NASDAQ · Healthcare · Biotechnology · US
$17.61
+0.17%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$17.75
From 52W high−51.46%
Volume2.90M
Market cap$3.42B
P/E (TTM)—
P/S (TTM)2.7x
Div yield—
Key dataSep 18, 2026
Open
$17.75
From 52W high
−51.46%
Volume
2.90M
Market cap
$3.42B
ValuationView details →
P/E (Fwd)
41.1x
EV/EBITDA
−378.0x
P/E (TTM)
—
RSI (14)
35.4
MomentumView details →
1D Return
+0.17%
YTD Return
−18.28%
SummaryUpdated Jun 1, 2026
Legend Biotech Corporation (NASDAQ:LEGN) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Somerset, New Jersey. The company is a subsidiary of Genscript Biotech Corporation and went public in June 2020. Legend Biotech specializes in developing innovative cell therapies, particularly CAR-T (Chimeric Antigen Receptor T-cell) therapies for treating various cancers and other diseases. The company has achieved significant commercial success with its lead product CARVYKTI, which has become a leading treatment for multiple myeloma, and continues to expand its pipeline of cell therapy candidates targeting both blood cancers and solid tumors.
Similar companies
Latest newsMore news →
Legend Biotech appointed Ingrid Zhang, a Novartis executive, as CEO, ending a nearly two-month search that began when former CEO Ying Huang resigned in July.5d agoLegend Biotech reported second-quarter 2026 results, achieving its first quarter of company-wide profitability on both IFRS and adjusted basis, with continued global growth for CARVYKTI.40d ago